Previous knowledge on melatonin use for pulmonary arterial hypertension has primarily been gathered from animal studies, with ...

Long-term exposure to particulate matter in patients with pulmonary arterial hypertension increases risk for lung transplantation or death.

Merrill H. Stewart, MD, Ochsner Health, explains how his practice takes advantage of downtime during cardiologist ...

Patients with pulmonary hypertension associated with congenital heart disease make up an increasing proportion of the total pulmonary hypertension population ... Accurate measurements of RV function ...

Pulmonary hypertension (PH) describes heterogeneous population of patients with a mean pulmonary arterial pressure >20 mm Hg. Rarely, PH presents as a primary disorder but is more commonly part of ...

Group 4: CTEPH (chronic thromboembolic pulmonary hypertension)—In some patients, pulmonary embolism, or blood clots, in the lung’s arteries can form scar-like tissue, blocking or narrowing the ...

Objectives The aim of our work was to identify specific patterns in clinical features and nailfold capillary changes that may help in screening for pulmonary arterial hypertension (PAH) in patients ...

Liquidia announces FDA approval and commercial launch of YUTREPIA for treating pulmonary arterial hypertension and PH-ILD. Quiver AI Summary. Liquidia Corporation has announced that its inhalation ...

Background Pulmonary hypertension (PH) is a progressive cardiopulmonary condition associated with increased morbidity and mortality. The extracellular matrix component hyaluronan (HA) is linked to ...

Keros Therapeutics will no longer develop the fusion protein cibotercept for pulmonary arterial hypertension, a move that the biotech on Thursday said triggered a 45% reduction in force.. The layoffs ...

A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be effective at preventing death in those with more advanced disease.